Psychiatrists estimate that just under half of prevalent
schizophrenia cases do not report their symptoms and seek treatment,
while one third of patients do not receive an accurate diagnosis. The
nature of schizophrenia complicates its presentation, as sufferers may
lack the drive or insight into their symptoms needed to seek help.
Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka) is the most commonly used antipsychotic brand for first- and second-line treatment of schizophrenia. In a market where treatment decisions are largely driven by safety profiles, Abilify is crucially associated with lower incidences of common antipsychotic side effects than some of its competitors.
The three latest antipsychotics to reach the market have all experienced very slow uptake and have so far failed to penetrate first-line therapy. Their underwhelming market shares reveal that the US schizophrenia drug market is now saturated with atypical antipsychotics and that the market not very receptive to new, undifferentiated treatments.
Your key questions answered
Report Details
Published: May 2012
No. of Pages: 81
Price: Single User License:US $ 7600 Corporate User License: US $ 19000
Table of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
COUNTRY TREATMENT TREES
Introduction to treatment trees
Seven major markets
US
Japan
France
Germany
Italy
Spain
UK
DISEASE DEFINITION AND DIAGNOSIS
Disease definition
Etiology
Environmental risk factors
Genetic risk factors
Pathophysiology of schizophrenia
Symptoms
Schizophrenia is typified by positive, negative, and cognitive symptoms
Presentation and diagnosis
Just over one in two prevalent schizophrenia sufferers report symptoms and seek treatment
One third of prevalent schizophrenia patients are either undiagnosed or misdiagnosed
Treatment rates
Schizophrenia has a higher pharmacological treatment rate than other common psychiatric disorders
Referral patterns
Schizophrenia is largely managed in specialist care
The Japanese referral pathway differs to those in the US and Europe
Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka) is the most commonly used antipsychotic brand for first- and second-line treatment of schizophrenia. In a market where treatment decisions are largely driven by safety profiles, Abilify is crucially associated with lower incidences of common antipsychotic side effects than some of its competitors.
The three latest antipsychotics to reach the market have all experienced very slow uptake and have so far failed to penetrate first-line therapy. Their underwhelming market shares reveal that the US schizophrenia drug market is now saturated with atypical antipsychotics and that the market not very receptive to new, undifferentiated treatments.
Your key questions answered
- How does each drug’s patient share vary by country and line of therapy?
- What can be done to influence the patient pathway to increase market share?
- What is the realistic patient population that a new market entrant can target?
- How have generic antipsychotics affected prescribing behaviors in the seven major markets?
- What proportion of patients experience treatment a complete response with currently available antipsychotics?
Report Details
Published: May 2012
No. of Pages: 81
Price: Single User License:US $ 7600 Corporate User License: US $ 19000
Table of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
COUNTRY TREATMENT TREES
Introduction to treatment trees
Seven major markets
US
Japan
France
Germany
Italy
Spain
UK
DISEASE DEFINITION AND DIAGNOSIS
Disease definition
Etiology
Environmental risk factors
Genetic risk factors
Pathophysiology of schizophrenia
Symptoms
Schizophrenia is typified by positive, negative, and cognitive symptoms
Presentation and diagnosis
Just over one in two prevalent schizophrenia sufferers report symptoms and seek treatment
One third of prevalent schizophrenia patients are either undiagnosed or misdiagnosed
Treatment rates
Schizophrenia has a higher pharmacological treatment rate than other common psychiatric disorders
Referral patterns
Schizophrenia is largely managed in specialist care
The Japanese referral pathway differs to those in the US and Europe
